Skip to main content

RenovoRx, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

RNXT$1.18+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Balance Sheets

(in thousands, except share and per share amounts)

December 31, 2025December 31, 2024
Assets
Current assets:
Cash and cash equivalents$7,024$7,154
Accounts receivable13943
Prepaid expenses324328
Inventory189-
Other current assets217303
Total current assets7,8937,828
Operating lease right-of-use asset190278
Property and equipment, net1212
Total assets$8,095$8,118
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$799$586
Accrued expenses and other current liabilities1,1631,323
Total current liabilities1,9621,909
Common stock warrant liability6041,519
Operating lease liability, net of current portion107212
Total liabilities2,6733,640
Commitments and contingencies
Stockholders' equity:
Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2025 and 2024, respectively; zero shares issued and outstanding at December 31, 2025 and 2024, respectively--
Common stock, $0.0001 par value; 250,000,000 shares authorized at December 31, 2025 and 2024, respectively; 36,613,916 and 24,034,672 shares issued and outstanding at December 31, 2025 and 2024, respectively42
Additional paid-in capital66,80554,695
Accumulated deficit(61,387)(50,219)
Total stockholders’ equity5,4224,478
Total liabilities and stockholders’ equity$8,095$8,118
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.